Oppenheimers give $5.5 million to French Hospital Medical Center
Story updated at 12:20 p.m. March 14: French Hospital Medical Center in San Luis Obispo has received a $5.5 million donation from Peter Oppenheimer, former chief financial officer of Apple, and his wife Mary Beth. The largest gift in the history of the hospital will be used to expand and modernize emergency services. “Built in Read More →
Gene technology raises ethical questions
By Frank Kalman A relatively obscure talk about genes was given at UC Santa Barbara recently by Dr. Siddhartha Mukherjee, a researcher and clinical oncologist at Columbia University and author of a Pulitzer Prize winning book, the “Emperor of all Maladies: A Biography of Cancer.” It was, however, on par in terms of gravity with Read More →
Amgen declares $1.15 per share dividend
The board of directors for Thousand Oaks biotechnology company Amgen declared a $1.15 per share dividend March 3 for the second quarter of 2017. The dividend will be paid on June 8 to all stockholders of record as of the close of business on May 17. The company has a market cap of $130.1 billion Read More →
Inogen reports huge increase in net income
Inogen, a maker of portable oxygen concentrators based in Goleta, announced a 77 percent increase in net income Feb. 28 on fourth quarter revenues of $50.9 million. Sales revenues grew 47.2 percent over the same quarter in 2015, to $42.6 million. Net income for the quarter was $5.3 million, bringing the company up to $20.5 Read More →
Genentech sues Amgen over biosimilar drug info
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
Amgen applies for FDA approval of Blincyto
Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014. “Acute Read More →
Drug sales for biotech giant Amgen boost bottom line
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
